Dialysis, cardiovascular disease, and the future

Hemodialysis International

Volumn 11, Issue SUPPL. 1, 2007, Pages

  Ritz, Eberhard ^a,b   Dikow, Ralf ^a   Gross, Marie Luise ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Nierenzentrum ^*  (Germany)

Author keywords

blockers; ACE inhibitors; Cardiomyopathy; Cardiovascular death; Hemodialysis; Myocardial infarction; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOSINOPRIL; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATE; PLACEBO; RAMIPRIL; TELMISARTAN; VITAMIN D;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DEPRESSION; FIBROSING ALVEOLITIS; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; META ANALYSIS; MICROANGIOPATHY; MINERAL METABOLISM; NONHUMAN; RENAL REPLACEMENT THERAPY; SLEEP DISORDER; SUDDEN DEATH; SYSTEMATIC REVIEW;

EID: 33947730788     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2007.00140.x     Document Type: Article

References (86)

1. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis. 2000; 35: S117-S131.
2. Scribner BH, Caner JEZ, Hegstrom R, Burnell JM. The treatment of chronic uremia by means of intermittent hemodialysis: A preliminary report. Trans Am Soc Artif Intern Organs. 1960; 6:114-122.
3. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int. 1992; 41:1286-1291.
4. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999; 33:507-517.
5. Zager PG, Nikolic J, Brown RH, et al. "U"curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic Inc. Kidney Int. 1998; 54:561-569.
6. Schomig M, Eisenhardt A, Ritz E. Controversy on optimal blood pressure on haemodialysis: Normotensive blood pressure values are essential for survival. Nephrol Dial Transplant. 2001; 16:469-474.
7. Dorhout Mees EJ. Volaemia and blood pressure in renal failure: Have old truths been forgotten. Nephrol Dial Transplant. 1995; 10:1297-1298.
8. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int. 2000; 58:2147-2154.
9. Guyton AC, Coleman TG. Quantitative analysis of the pathophysiology of hypertension. 1969. J Am Soc Nephrol. 1999; 10:2248-2258.
10. Titze J, Krause H, Hecht H, et al. Reduced osmotically inactive Na storage capacity and hypertension in the Dahl model. Am J Physiol Renal Physiol. 2002; 283:F134-F141.
11. Kitiyakara C, Chabrashvili T, Chen Y, et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol. 2003; 14:2775-2782.
12. Chaparzadeh N, D'Amico ML, Khavari-Nejad RA, Izzo R, Navari-Izzo F. Antioxidative responses of Calendula officinalis under salinity conditions. Plant Physiol Biochem. 2004; 42:695-701.
13. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62:1524-1538.
14. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet. 1999; 353:1838-1842.
15. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974; 290:697-701.
16. Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein e knockout mouse: A model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol. 2003; 14:311-316.
17. Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB. Chronic renal failure accelerates atherogenesis in apolipoprotein e-deficient mice. J Am Soc Nephrol. 2003; 14:2466-2474.
18. Bursztyn M, Motro M, Grossman E, Shemesh J. Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: A 3-year prospective observation. J Hypertens. 2003; 21:1953-1959.
19. Karra R, Vemullapalli S, Dong C, et al. Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci USA. 2005; 102:16789-16794.
20. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340:115-126.
21. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353:999-1007.
22. Bahlmann FH, DeGroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003; 64:1648-1652.
23. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004; 110:1006-1012.
24. Herbrig K, Pistrosch F, Oelschlaegel U, et al. Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis. 2004; 44: 840-849.
25. Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004; 103:921-926.
26. Raine AE, Margreiter R, Brunner FP, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant. 1992; 7(Suppl2): 7-35.
27. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296-1305.
28. Ritz E, McClellan WM. Overview: Increased cardiovascular risk in patients with minor renal dysfunction: An emerging issue with far-reaching consequences. J Am Soc Nephrol. 2004; 15:513-516.
29. Wanner Ch KV, März W, Olschewski M, Mann JFE, Ruf G, Ritz E. Statin treatment in patients with type 2 diabetes mellitus on dialysis may come too late. N Engl J Med. 2005; 353:1858-1860.
30. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996; 11:1277-1285.
31. Amann K, Tyralla K, Gross ML, et al. Cardiomyocyte loss in experimental renal failure: Prevention by ramipril. Kidney Int. 2003; 63:1708-1713.
32. Rambausek M, Ritz E, Mall G, Mehls O, Katus H. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int. 1985; 28:775-782.
33. Yamamoto M, Yang G, Hong C, et al. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest. 2003; 112:1395-1406.
34. Amann K, Tornig J, Buzello M, et al. Effect of antioxidant therapy with dl-alpha-tocopherol on cardiovascular structure in experimental renal failure. Kidney Int. 2002; 62:877-884.
35. Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 1994; 4:1814-1819.
36. Amann K, Tornig J, Kugel B, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003; 63:1296-1301.
37. Nabokov AV, Amann K, Wessels S, Munter K, Wagner J, Ritz E. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int. 1999; 55:512-519.
38. Amann K, Ritz E. Microvascular disease - the Cinderella of uraemic heart disease. Nephrol Dial Transplant. 2000; 15:1493-1503.
39. Carmeliet P, Ng YS, Nuyens D, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med. 1999; 5:495-502.
40. Dikow R, Kihm LP, Zeier M, et al. Increased infarct size in uremic rat: Reduced ischemia tolerance? J Am Soc Nephrol. 2004; 15:1530-1536.
41. Ritz E, Koch M. Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis. 1993; 21:113-118.
42. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998; 31:607-617.
43. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12:2131-2138.
44. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16:520-528.
45. Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism - an update. Eur J Clin Invest. 1998; 28:271-276.
46. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004; 66: 2010-2016.
47. Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol. 2005; 16:210-218.
48. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol. 1994; 14:219-231.
49. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110:229-238.
50. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol. 2005; 16:1115-1125.
51. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004; 15:411-419.
52. Degoulet P, Legrain M, Reach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron. 1982; 31:103-110.
53. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990; 15:458-482.
54. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA. 2004; 291:451-459.
55. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361:2024-2031.
56. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003; 361:1149-1158.
57. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004; 110:1557-1563.
58. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002; 61:297-304.
59. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1425-1435.
60. Holmberg B, Brannstrom M, Bucht B, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scand J Urol Nephrol. 2005; 39:503-510.
61. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis. 2002; 40:1023-1029.
62. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001; 38:85-90.
63. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001; 59:1128-1133.
64. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000; 11:556-564.
65. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med. 2003; 139:105-112.
66. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis. 2004; 43:1056-1064.
67. Koch M, Thomas B, Tschope W, Ritz E. Survival and predictors of death in dialysed diabetic patients. Diabetologia. 1993; 36:1113-1117.
68. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol. 2003; 41:1438-1444.
69. Lopes AA, Bragg J, Young E, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int. 2002; 62:199-207.
70. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML. Depression as an antecedent to heart disease among women and men in the NHANES I study. National health and nutrition examination survey. Arch Intern Med. 2000; 160:1261-1268.
71. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996; 94:3123-3129.
72. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): Case-control study. Lancet. 2004; 364:953-962.
73. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry. 1998; 155:4-11.
74. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998; 55:580-592.
75. Everson-Rose SA, Meyer PM, Powell LH, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care. 2004; 27:2856-2862.
76. Somers VK. Sleep - a new cardiovascular frontier. N Engl J Med. 2005; 353:2070-2073.
77. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005; 353:2034-2041.
78. Kimmel PL, Miller G, Mendelson WB. Sleep apnea syndrome in chronic renal disease. Am J Med. 1989; 86:308-314.
79. Pressman MR, Benz RL, Schleifer CR, Peterson DD. Sleep disordered breathing in ESRD: Acute beneficial effects of treatment with nasal continuous positive airway pressure. Kidney Int. 1993; 43:1134-1139.
80. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993; 328:1230-1235.
81. Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol. 2002; 13:729-733.
82. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003; 42:925-931.
83. Chan CT, Hanly P, Gabor J, Picton P, Pierratos A, Floras JS. Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Kidney Int. 2004; 65:661-665.
84. Chan CT, Jain V, Picton P, Pierratos A, Floras JS. Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int. 2005; 68:338-344.
85. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med. 2001; 344:102-107.
86. Scribner BH. Lasker Clinical Medicine Research Award. Medical dilemmas: The old is new. Nat Med. 2002; 8:1066-1067.